Tumor-targeted nanodrug FSGG/siGal-9 for transdermal photothermal immunotherapy of melanoma

Published in Cancer
Tumor-targeted nanodrug FSGG/siGal-9 for transdermal photothermal immunotherapy of melanoma

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

T cells in the context of cancer become exhausted and dysfunctional due to persistent immune checkpoints/co-inhibitory signals such as PD-L1/PD-1, Gal-9/TIM-3, HVEM/BTLA, and CD155/TIGIT pathways. Exhausted T cells lose robust effector functions, express IRs including PD-1, TIM-3, BTLA, CTLA-4, LAG-3, TIGIT, and decline in the secretion of functional cytokines IFN-γ, TNF-α and IL-2. It is discovered that exhausted T cells are responsive to reinvigoration of immune responses by blockade of the PD-L1/PD-1 pathway. For melanoma clinic treatment, two anti-PD-1 antibodies, nivolumab and pembrolizumab, were approved by the US FDA in 2014 for the treatment of metastatic melanoma but have been shown to produce objective response in just 30-40% of patients. In 2019, studies discovered that Gal-9/TIM-3 pathway is the key mechanism of resistance to anti-PD-1 immunotherapy in lung cancer patients.

Gal-9 is highly expressed in normal tissues and associates with body immune tolerance, and was firstly evidenced with much higher expression on the primary solid tumors than CD80/86 (B7) and CD274 (PD-L1) here, which suggests that Gal-9 may be a key factor in inhibiting the anti-tumor immunity, and its receptor T cell immunoglobulin and mucin domain 3 (TIM-3) was discovered on CTL with high expression as well based on the single cell analysis. The immune checkpoint communications showed that the Gal-9/TIM-3 axis played the most vital role on negatively regulating the anti-tumor immunity of CTL for melanoma.

Then, we used a novel transdermal photothermal nanosensitizer (FSGG) loading Gal-9 siRNA (FSGG/siGal-9) for knocking the tumor cells down Gal-9 to block the Gal-9/TIM-3 axis and prohibit CTL exhaustion synergizing PTT against melanoma, which evidenced good effects on inhibiting tumor growth and enhancing anti-tumor immunity, named “photothermal immunotherapy”. The nanostructure FSGG/siGal-9 possesses comparative photothermal effects with GNR, proper size about ~111.67 nm diameter, good targetability and biocompatibility, and easily eliminating from the body. 

Besides exosomes derived from siGal-9-inhibiting immune checkpoint (Gal-9) tumor cells further promoted anti-tumor immunity for the photothermal immunotherapy, although heat (44 oC)-treated tumor cells are induced to release more exosomes.

This paper provides a new perspective for tumor prevention and treatment.


PD-L1: Programmed death ligand 1; PD-1: Programmed death 1; Gal-9: Galectin-9; TIM-3: T cell immunoglobulin and mucin domain 3; HVEM: Herpesvirus entry mediator; BTLA: B and T lymphocyte attenuation factor; TIGIT: T cell immunoglobulin and ITIM domain protein; IRs: Inhibitory receptors; CTLA-4: Cytotoxic T lymphocyte associated antigen 4; LAG-3: Lymphocyte activation gene; IFN-γ: Interferon-γ; TNF-α: Tumor necrosis factor-α; IL-2: Interleukin-2; CTL: Cytotoxic T lymphocytes; FSGG: Fe3O4@SiO2-GNR-Glu; GNR: Gold nanorod.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Cancer Therapy
Life Sciences > Biological Sciences > Cancer Biology > Cancer Therapy
Cancer Nanotechnology
Life Sciences > Biological Sciences > Cancer Biology > Cancer Nanotechnology
Cancer Immunotherapy
Life Sciences > Biological Sciences > Cancer Biology > Cancer Therapy > Cancer Immunotherapy
Skin Cancer
Life Sciences > Biological Sciences > Cancer Biology > Cancers > Skin Cancer

Related Collections

With collections, you can get published faster and increase your visibility.

Tumour microenvironment

This Collection welcomes submissions on the interplay between tumours and their microenvironment, as well as how these interactions impact on cancer therapy.

Publishing Model: Open Access

Deadline: Sep 07, 2024